Skip to main content

Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia News

News
07/31/2023
Julie Gould
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be...
07/31/2023
First Report Managed Care
News
07/14/2023
Jolynn Tumolo
New research indicates that adding an anti-CD20 monoclonal antibody to a BTK inhibitor in patients with untreated or relapsed/refractory CLL could provide significantly superior efficacy with an equally safe profile.
New research indicates that adding an anti-CD20 monoclonal antibody to a BTK inhibitor in patients with untreated or relapsed/refractory CLL could provide significantly superior efficacy with an equally safe profile.
New research indicates that...
07/14/2023
First Report Managed Care
News
06/23/2023
Jolynn Tumolo
Researchers studied the efficacy and tolerability of obinutuzumab plus bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia.
Researchers studied the efficacy and tolerability of obinutuzumab plus bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia.
Researchers studied the efficacy...
06/23/2023
First Report Managed Care

Advertisement

News
06/22/2023
Jolynn Tumolo
For the study, patients who were heavily pretreated for chronic lymphocytic leukemia received ceralasertib with vs without acalabrutinib.
For the study, patients who were heavily pretreated for chronic lymphocytic leukemia received ceralasertib with vs without acalabrutinib.
For the study, patients who were...
06/22/2023
First Report Managed Care
News
05/23/2023
Jolynn Tumolo
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved...
05/23/2023
First Report Managed Care
News
05/19/2023
Jolynn Tumolo
When compared to White patients, Black patients with chronic lymphocytic leukemia face a persistent survival disadvantage that is not found among other racial minority groups, researchers reported.
When compared to White patients, Black patients with chronic lymphocytic leukemia face a persistent survival disadvantage that is not found among other racial minority groups, researchers reported.
When compared to White patients,...
05/19/2023
First Report Managed Care

Advertisement

News
04/24/2023
Jolynn Tumolo
“Further studies should explore other socioeconomic and cultural factors that may drive these racial disparities, as well as the safety and effectiveness of treatments by race, to better understand how racial disparities might impact patient...
“Further studies should explore other socioeconomic and cultural factors that may drive these racial disparities, as well as the safety and effectiveness of treatments by race, to better understand how racial disparities might impact patient...
“Further studies should explore...
04/24/2023
First Report Managed Care
News
04/19/2023
Jolynn Tumolo
Researchers studied survival outcomes in patients who were treated with either ibrutinib or idelasib plus rituximab after receiving 2 previous lines of therapy.
Researchers studied survival outcomes in patients who were treated with either ibrutinib or idelasib plus rituximab after receiving 2 previous lines of therapy.
Researchers studied survival...
04/19/2023
First Report Managed Care
News
03/27/2023
Jolynn Tumolo
“In cases with a diagnosis of CLL, care should be taken to detect other malignancies,” researchers wrote, “and it should be kept in mind that the presence of other malignancies may reduce survival.”
“In cases with a diagnosis of CLL, care should be taken to detect other malignancies,” researchers wrote, “and it should be kept in mind that the presence of other malignancies may reduce survival.”
“In cases with a diagnosis of...
03/27/2023
First Report Managed Care

Advertisement

News
03/03/2023
Maria Asimopoulos
In light of real-world data, researchers studied outcomes and prognoses in patients with chronic lymphocytic leukemia who received ibrutinib monotherapy.
In light of real-world data, researchers studied outcomes and prognoses in patients with chronic lymphocytic leukemia who received ibrutinib monotherapy.
In light of real-world data,...
03/03/2023
First Report Managed Care

Advertisement